长春瑞滨联合顺铂治疗晚期乳腺癌的临床观察

目的探讨长春瑞滨联合顺铂治疗经紫杉醇＋蒽环类联合化疗失败的局部晚期乳腺癌和复发转移乳腺癌的疗效及安全性。方法10例采用紫杉醇＋蒽环类化疗耐药的局部晚期乳腺癌和31例手术后紫杉醇＋蒽环类辅助治疗的转移性乳腺癌患者，应用长春瑞滨（25mg／m^2，第1，8天，静脉滴注）、顺铂（30mg／m^2，第1—3天，静脉滴注）化疗，对其疗效及不良反应进行分析。结果全组患者完全缓解6例（14．6％），部分缓解17例（41．5％）。不良反应以骨髓抑制、消化道反应常见。结论长春瑞滨联合顺铂方案对蒽环类和（或）紫杉醇耐药的乳腺癌疗效较好，值得临床进一步研究。

Application of vinorelbine-cisplatin combination in treatment for locally advanced breast cancer and advanced breast cancer patients by using neoadjuvant chemotherapy

Objective To evaluate the efficacy and tolerability of vinorelbine combined with cisplatin in the treatment for locally advanced breast cancer and advanced breast cancer with post-operation by using adjuvant chemotherapy including reviously treated with anthracyclines or taxanes.Methods 10 patients of locally advanced breast cancer and 31 patients of advanced breast cancer received vinorelbine 25mg/m2,iv,d 1,d8;combined with cisplatin 25mg/m2,iv,d 1-3 and repeated every 3 weeks.ResultsIt shows that the complete remission and the partial remission were 14.6% and 41.5%,The major side effects were myelosuppression,nausea and vomiting.Conclusions Vinorelbine combined with cisplatin is efficacious in advanced breast cancer patient failed to anthracy-clines and taxanes,and toxicities are well tolerated.